Copper-catalyzed tandem aerobic oxidative cyclization for the synthesis of 4-cyanoalkylpyrrolo[1,2-<i>a</i>]quinoxalines from 1-(2-aminophenyl)pyrroles and cyclobutanone oxime esters
作者:Zhenyu An、Yong Jiang、Xin Guan、Rulong Yan
DOI:10.1039/c8cc06256k
日期:——
A copper-catalyzed tandem ring-opening/cyclization reaction for the synthesis of 4-cyanoalkylpyrrolo[1,2-a]quinoxalines from 1-(2-aminophenyl)pyrroles and cyclobutanone oxime esters has been developed. This reaction involves C–C bond cleavage and C–C and C–N bond constructions with good functional group tolerance. A wide range of products are obtained in moderate to good yields under mild conditions
已开发了一种铜催化串联开环/环化反应,用于由1-(2-氨基苯基)吡咯和环丁酮肟酯合成4-氰基烷基吡咯并[1,2- a ]喹喔啉。该反应涉及C–C键断裂以及具有良好官能团耐受性的C–C和C–N键结构。在温和的条件下,可以以中等到良好的产率获得各种各样的产品。
TFAA‐Catalyzed Annulation Synthesis of Spiro Pyrrolo[1,2‐
<i>a</i>
]quinoxaline Derivatives from 1‐(2‐Aminophenyl)pyrroles and Benzoquinones/Ketones
作者:Jixiang Ni、Yong Jiang、Zhenjie Qi、Rulong Yan
DOI:10.1002/asia.201900567
日期:——
A metal-free trifluorosulfonate anhydride (TFAA)-catalyzed strategy for the synthesis of spiro pyrrolo[1,2-a]quinoxalines from 1-(2-aminophenyl)pyrroles and benzoquinones/ketones has been developed. With this general method, spiro pyrrolo[1,2-a]quinoxalines have been accessed via nucleophilic addition and cyclization. This reaction exhibits good functional group tolerance, and a wide range of products
La présente invention concerne les composés de formule (I) :
dans laquelle A et R₁ sont tels que définis dans la description.
Médicaments.
本发明涉及式(I)化合物:
其中 A 和 R₁ 如描述中所定义。
药物。
Novel and Selective Partial Agonists of 5-HT<sub>3</sub> Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
In continuation of our previous work on piperazinopyrrolothienopyrazine derivatives, three series of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrrolaquinoxalines were prepared and evaluated as 5-HT3 receptor ligands. The chemical modifications performed within these new series led to structure-activity relationships regarding both high affinity and selectivity for the 5-HT3 receptors that are in agreement with those established previously for the pyrrolothienopyrazine series. The best compound (8a) obtained in these new series is in the picomolar range of affinity for 5-HT3 receptors with a selectivity higher than 10(6). Four of the high-affinity 5-HT3 ligands (8a, 15a,b, and 16d) were selected in both the pyridopyrrolopyrazine and the pyrroloquinoxaline series and were characterized in vitro and in vivo as agonists or partial agonists. Compound 8a was also evaluated in the light/dark test where it showed potential anxiolytic-like activity at very low doses per os.